Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAG NYSE:CLDI NASDAQ:IPA NASDAQ:ORMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$1.90+3.8%$1.86$1.33▼$3.58$86.21M0.7467,606 shs906,995 shsCLDICalidi Biotherapeutics$0.57-1.2%$0.38$0.20▼$3.89$20.78M0.944.26 million shs4.99 million shsIPAImmunoPrecise Antibodies$1.82-8.1%$0.87$0.27▼$2.32$90.61M0.442.61 million shs3.97 million shsORMPOramed Pharmaceuticals$2.09-1.9%$2.18$1.82▼$3.09$87.01M1.59141,150 shs81,490 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene+2.70%+0.53%-2.56%+20.25%-30.40%CLDICalidi Biotherapeutics-1.21%+70.75%+65.80%+23.01%-67.13%IPAImmunoPrecise Antibodies-8.08%+3.41%+159.44%+326.23%+86.28%ORMPOramed Pharmaceuticals-1.88%0.00%-1.88%-5.00%-17.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAGAdagene2.4959 of 5 stars3.35.00.00.01.81.70.0CLDICalidi Biotherapeutics0.5662 of 5 stars0.03.00.00.02.80.00.6IPAImmunoPrecise Antibodies2.9962 of 5 stars3.55.00.00.03.20.00.6ORMPOramed Pharmaceuticals1.0336 of 5 stars0.04.00.00.02.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 2.50Moderate Buy$8.00321.05% UpsideCLDICalidi Biotherapeutics 0.00N/AN/AN/AIPAImmunoPrecise Antibodies 3.00Buy$4.00119.78% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$100K895.09N/AN/A$1.14 per share1.67CLDICalidi BiotherapeuticsN/AN/AN/AN/A($2.32) per shareN/AIPAImmunoPrecise Antibodies$18.16M4.59N/AN/A$0.93 per share1.96ORMPOramed Pharmaceuticals$1.34M63.71N/AN/A$3.61 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$33.42MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)CLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/AIPAImmunoPrecise Antibodies-$20.13M-$1.16N/AN/AN/A-190.76%-88.87%-49.26%7/17/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)Latest CLDI, ORMP, ADAG, and IPA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/AORMPOramed Pharmaceuticals-$0.01N/AN/AN/AN/AN/A8/4/2025Q4 2025IPAImmunoPrecise Antibodies-$0.02N/AN/AN/AN/AN/A5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/ACLDICalidi BiotherapeuticsN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.012.302.30CLDICalidi BiotherapeuticsN/A0.190.19IPAImmunoPrecise Antibodies0.452.322.11ORMPOramed PharmaceuticalsN/A23.9423.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%CLDICalidi Biotherapeutics12.53%IPAImmunoPrecise Antibodies6.70%ORMPOramed Pharmaceuticals12.73%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%CLDICalidi Biotherapeutics6.70%IPAImmunoPrecise Antibodies6.83%ORMPOramed Pharmaceuticals13.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.11 million37.12 millionNot OptionableCLDICalidi Biotherapeutics3836.32 million20.04 millionN/AIPAImmunoPrecise Antibodies8045.76 million42.64 millionNot OptionableORMPOramed Pharmaceuticals1040.85 million35.25 millionOptionableCLDI, ORMP, ADAG, and IPA HeadlinesRecent News About These CompaniesORMP - Oramed Pharmaceuticals Inc Trailing Returns - MorningstarJuly 2, 2025 | morningstar.comMOramed Pharmaceuticals Inc. (ORMP) - Yahoo FinanceJuly 2, 2025 | ca.finance.yahoo.comORMP - Oramed Pharmaceuticals Inc Executives - MorningstarJune 27, 2025 | morningstar.comMWe're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn RateJune 27, 2025 | finance.yahoo.comOramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above Fifty Day Moving Average - Should You Sell?June 24, 2025 | marketbeat.comOramed Pharm Extends Stock Buyback ProgramMay 21, 2025 | tipranks.comThe past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitableMay 17, 2025 | finance.yahoo.comOramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalApril 28, 2025 | finanznachrichten.deAlpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed PharmaceuticalsApril 28, 2025 | globenewswire.comOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalApril 28, 2025 | prnewswire.comORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 TrialApril 3, 2025 | finance.yahoo.comOramed Pharmaceuticals And 2 Other Penny Stocks With Promising PotentialMarch 15, 2025 | finance.yahoo.comOramed Pharmaceuticals Issues Letter to ShareholdersMarch 4, 2025 | prnewswire.comOraMed Enters Global Licensing Deal for Lidocaine ProductMarch 1, 2025 | investing.comCongressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals StockFebruary 27, 2025 | benzinga.comOramed Pharmaceuticals to Spin Off Its Protein Oral Delivery TechnologyFebruary 11, 2025 | contractpharma.comCOraTech to pioneer oral insulin with $75 million investmentFebruary 11, 2025 | msn.comOramed enters JV for insulin development and commercializationFebruary 11, 2025 | markets.businessinsider.comOramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral InsulinFebruary 11, 2025 | prnewswire.comScilex announces early installment payment on senior secured promissory noteDecember 16, 2024 | markets.businessinsider.comORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent AgreementsDecember 2, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLDI, ORMP, ADAG, and IPA Company DescriptionsAdagene NASDAQ:ADAG$1.90 +0.07 (+3.83%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.81 -0.09 (-4.74%) As of 07/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Calidi Biotherapeutics NYSE:CLDI$0.57 -0.01 (-1.21%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$0.58 +0.00 (+0.70%) As of 07/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.ImmunoPrecise Antibodies NASDAQ:IPA$1.82 -0.16 (-8.08%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.84 +0.02 (+1.10%) As of 07/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Oramed Pharmaceuticals NASDAQ:ORMP$2.09 -0.04 (-1.88%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.11 +0.02 (+1.15%) As of 07/15/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
